Systemic Delivery and Biodistribution of Cisplatin in Vivo
This work was supported by the National Institute on Deafness and Other Communication Disorders (R21 DC010231; R01 DC012588) and the National Center for Research Resources (RR025512) at the National Institutes of Health for elemental analysis and by the National Science Foundation (Grant 0741993) for the purchase of the LTQ-Orbitrap Discovery.
Cisplatin is widely used to treat a variety of cancers. However, ototoxicity and nephrotoxicity remain serious side effects of cisplatin-based chemotherapy. In order to inform the study of cisplatin’s off-target effects, a new drug–fluorophore conjugate was synthesized that exhibited utility as a tracer to determine the cellular uptake and in vivo distribution of cisplatin. This probe will serve as a useful tool to facilitate investigations into the kinetics and biodistribution of cisplatin and its associated side effects in preclinical models after systemic administration.
Locate the Document
Chu, Y., Sibrian-Vazquez, M., Escobedo, J. O., Phillips, A. R., Dickey, D. T., Wang, Q., & ... Strongin, R. M. (2016). Systemic Delivery and Biodistribution of Cisplatin in Vivo. Molecular Pharmaceutics, 13(8), 2677-2682.